Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-029394
Filing Date
2023-08-14
Accepted
2023-08-14 16:24:28
Documents
62
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q eigr-20230630.htm   iXBRL 10-Q 1246821
2 EX-10.2 eigr-2023x06x30ex102.htm EX-10.2 45451
3 EX-10.3 eigr-2023x06x30ex103.htm EX-10.3 56819
4 EX-31.1 eigr-2023x06x30ex311.htm EX-31.1 9695
5 EX-31.2 eigr-2023x06x30ex312.htm EX-31.2 9702
6 EX-32.1 eigr-2023x06x30ex321.htm EX-32.1 5329
  Complete submission text file 0001628280-23-029394.txt   6150318

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eigr-20230630.xsd EX-101.SCH 42437
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT eigr-20230630_cal.xml EX-101.CAL 65116
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT eigr-20230630_def.xml EX-101.DEF 195378
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eigr-20230630_lab.xml EX-101.LAB 631906
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eigr-20230630_pre.xml EX-101.PRE 384810
56 EXTRACTED XBRL INSTANCE DOCUMENT eigr-20230630_htm.xml XML 663348
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 231170738
SIC: 2836 Biological Products, (No Diagnostic Substances)